The QMN Weekly Bulletin

Indevus Pharmaceuticals suffered another setback relating to the reintroduction of its bladder cancer treatment Valstar as manufacturing issues are preventing approval of the product.

Bayer Healthcare Diabetes Care is recalling test strips for its Contour TS Blood Glucose Meter because some strips could lead to glucose readings that are 5 percent to 17 percent higher than actual levels.

E Med Future, which manufactures NeedleZap needle disintegration devices, has operated for the past two years without a quality system, complaint procedures or quality audits, according to an FDA warning letter.

Hikal has signed a long-term agreement with global pharma major Pfizer Inc. for the manufacture and supply of active pharmaceutical ingredients (APIs).

Strides Arcolab Limited, a global pharmaceutical company based in India, announced that its loss-making manufacturing operation for OTC & nutraceuticals for soft gelatin products in the U.S. (conducted through its subsidiary, Strides Inc.) has been shut down.

Quintiles Transnational Corp. announced the expansion and consolidation of its Global Central Laboratories and Clinical Development Services units in Beijing to accommodate their growing business in China.

BioMérieux announces the transfer to France of R&D and certain manufacturing activities currently at its Boxtel site in the Netherlands.

The $8-billion Daiichi Sankyo Company, Japan’s second-largest pharma company, is in the process of setting up a full-fledged manufacturing and research operation in the country.

Millipore Corporation and Gen-Probe announced the launch of the first product from their ground-breaking collaboration to create faster, sensitive, more robust tests for detecting contaminants in pharmaceutical and biotechnology manufacturing processes.